Lupin’s investments in Research and Development (R&D) have helped us gain a leadership position in differentiated product introductions and become a formidable player in the generics space.
This website page is targeted to a wide range of audiences
This link will take you to a non-Lupin UK website. Lupin does not recommend, endorse or accept liability for sites controlled by third-parties.
This link will take you to another Lupin Healthcare UK provided website.
Lupin’s investments in Research and Development (R&D) have helped us gain a leadership position in differentiated product introductions and become a formidable player in the generics space.
At Lupin, we are embracing advanced technologies, scientific breakthroughs and partnerships that enable us to advance research and development towards building a diversified portfolio and gain a leadership position in important new product introductions. Our Research & Development helps build a solid foundation as we progress to become a Complex Generics, Biosimilars and Specialty front runner.
Lupin has a solid team of 1,700 scientists and technologists employed at state-of-the-art facilities across the world. We are well on track to emerge as an innovation-led transnational pharmaceutical organisation providing affordable healthcare solutions with uncompromising quality. Within Europe, Nanomi, a Lupin business, leads the field in nanoparticle manufacture and complex injectable development.
Lupin’s research scientists have a proven track record of delivering high-quality technology-intensive products, Active Pharmaceutical Ingredients (APIs), formulations and newer dispensation forms.
Data protection of French SNDS studies.
Lupin conducts clinical research in many countries. The downloadable documents below give information on the protection of personal data regarding studies requiring access to data from the French National Health Data System.